Diligence memo · auto-generated · as of July 2, 2026
Vicept Therapeutics, Inc.
Vicept Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Vicept Therapeutics, Inc. operates in Pharmaceuticals, based in Malvern.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vicept Therapeutics, Inc. has raised $22M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2009-08-04.
Most recent recorded round closed around 2009-08-04.
Valuation (modeled)modeled
Provath models Vicept Therapeutics, Inc. at approximately $537M (range $33M–$2.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.63× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 16.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 68% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Glycomimetics Inc, Avid Radiopharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., Sirion Holdings, Inc., Viamet Pharmaceuticals Inc.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.